Boehringer Ingelheim is a pharmaceutical company with revenue of 27.8 billion euros in 2025. It still belongs to the descendants of its founder, Albert Boehringer. A great-grandson of the founder, Hubertus vom Baumbach, led its board until the summer of 2025. In September 2026 the chief executive, Shashank Deshpande, ruled out a stock market listing: Boehringer Ingelheim strebt keine Börsenlistung an. Boehringer Ingelheim does not seek a stock market listing. He also said: Ein Verkauf oder IPO ist nicht geplant. A sale or IPO is not planned. To the magazine Manager Magazin he explained: Wir sind nicht von externen Investoren oder Kapitalgebern abhängig, wir denken in Generationen, nicht in Quartalen. We do not depend on outside investors or lenders. We think in generations, not in quarters.